Blackhawk Growth’s MindBio Therapeutics Signs Collaboration Agreement With Digital Mind Technology
Vancouver, British Columbia – September 29, 2021 – Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that its subsidiary, MindBio Therapeutics, has signed an agreement with Digital Mind Technology Pty Ltd, (“Digital Mind”) a medical research and technology company developing evidence-based digital interventions to improve mental health and wellbeing. The agreement will see the two companies collaborate on product development and the commercialization of intellectual property.
Digital Mind’s foundational research and product development is creating new digital models to intervene in pain management experienced in cancer patients. Digital Mind’s platform and technology will provide unique opportunities to empower patients to adopt healthy self-care behavior for long-term wellbeing. Cancer survivorship brings unique challenges related to self-care and health services utilization. Digital interventions can address these challenges through personalized information tailored to individual needs and accessible at people’s own convenience via mobile devices.
Digital Mind was founded by Chief Scientist Dr. Lahiru Russell PhD. Dr. Russell’s vision is to empower people to engage in healthy self-care strategies to manage the impact of their illness for their long-term wellbeing.
Dr. Russell graduated with a Master in Biochemistry from the University of Geneva, Switzerland. Dr. Russell has worked for a decade in the pharmaceutical industry managing clinical trials. Over the years, Dr. Russell developed an interest in the psychosocial adaptation to illness and strategies to manage stress-related aspects of diseases. Her studies in Epidemiology at the London School of Hygiene and Tropical Medicine (UK) stimulated her desire to undertake research in this field. Following this, Dr. Russell joined the psycho-oncology research team at the Peter MacCallum Cancer Centre in Melbourne, Australia, evaluating supportive care interventions for people affected by cancer.
“Digital Mind Technology will be a great platform to advance research and launch new digital mind-body therapies” said Dr. Lahiru Russell. “We aim to build a strong body of evidence around the beneficial impact of these therapies on the mental health of people with chronic conditions. Our collaboration with MindBio will transform the way people manage their health.”
Coupling her personal interest in mindfulness practices and her professional experience in psycho-oncology, Dr. Russell’s PhD research was designed to determine whether a mindfulness program could benefit people with melanoma. The focus of the program was to empower participants to manage their health by promoting awareness of emotions and teaching skills to manage distressing thoughts. Central to the success of the program was the flexibility offered to participants to access the information at their own convenience.
Executive Director of MindBio Therapeutics, Justin Hanka says: “MindBio is evolving into a multidisciplinary company involved in integrating research & clinical trials, clinics, technology and digital therapies. We are excited to have signed an agreement with Digital Mind Technology to expand MindBio’s footprint into technology and digital therapeutics that benefits people with mental health and chronic conditions.”
About Blackhawk Growth
Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.
The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A
Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.
For further information please contact:
Frederick Pels, Chief Executive Officer
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.